At the recent JP Morgan (JPM) Healthcare Conference, it connected with numerous C-level executives from global pharmaceutical giants. Key decision-makers showed significant interest in the technology. At this rate, it expects to see revenue from NS101 by 2030.
Neuracle Science, a pioneering drug development firm, is approaching a critical juncture for boosting its corporate value. The company aims to advance its preclinical and domestic clinical trials for the antibody drug NS101, which targets the FAM19A5 protein. Simultaneously, it’s pursuing a KOSDAQ listing to propel itself to new heights.
Established in 2015 by Dr. Sung Jae-young, a professor at Korea University’s School of Medicine, Neuracle Science is a biotech startup focused on developing novel therapeutics. The company is tackling the complex challenge of degenerative neurological diseases with its innovative drug candidates.
Neuracle Science is developing a drug pipeline targeting degenerative brain disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Their primary focus is on protein-based therapies to restore neural function and repair damage, as well as developing biomarkers for early diagnosis.
Dr. Sung’s research team discovered that the protein FAM19A5, secreted by brain cells, is a key factor in synaptic dysfunction. They developed NS101, an antibody treatment candidate designed to inhibit this effect. The team plans to validate NS101’s efficacy through a series of clinical trials.
Currently, they are conducting clinical trials for idiopathic sudden sensorineural hearing loss as their initial target. A Phase 1a trial has been completed in North America, and a combined Phase 1/2 trial is underway in South Korea, involving both healthy adults and patients with sudden hearing loss. Topline results are expected soon.
Networking at the JPM Healthcare Conference
To facilitate global expansion, Neuracle Science participated in the recent JPM Healthcare Conference in San Francisco. The company showcased its technology during the Global IR session organized by the Korea Biotechnology Industry Organization.
In an interview with News1 at the event, Chief Financial Officer (CFO) Jang Gi-cheol stated that they had the opportunity to meet with numerous C-level executives from global companies interested in the work. The value lies in meeting multiple decision-makers simultaneously, rather than the sheer number of meetings. It was invaluable to interact with leaders from various sectors, including clinical research, research and development (R&D), and business development.
Jang added that they’re the only company in South Korea conducting clinical trials for an antibody treatment targeting hearing loss. With less competition, patient recruitment is easier, allowing for faster clinical trial progression. It is garnering significant interest from major pharmaceutical companies, and there’s high potential for technology licensing deals.
Neuracle Science is pursuing an initial public offering (IPO) based on its groundbreaking technology. In 2023, the company passed a technology assessment and successfully raised 7.6 billion KRW (approximately 5.2 million USD) in pre-IPO funding in May 2024. NH Investment & Securities is underwriting the IPO. A successful listing is expected to accelerate the development of additional innovative drugs.
CFO Jang emphasized that they’re committed to securing global partnerships and successfully completing the KOSDAQ listing. The goal is to establish ourselves as a leading global biotech company in the neurological disease field within the next few years by intensifying its research and commercialization efforts.